Despite promising preclinical results, CSF-1R inhibitors have shown limited efficacy in clinical trials for glioblastoma [85] as in fact resistance to CSF-1R blockade is often observed, driven by compensatory mechanisms within the TME, including increased insulin-like growth factor-1 (IGF-1) signaling. The gene discussed is CSF1R; the disease is glioblastoma.